Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors

This study will evaluate the utility of ctDNA detection in patients with high-risk stage I, stage II, and stage III germ cell tumor disease to develop a tool for post-treatment cancer cell detection.

Lead sponsor: Indiana University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Kathleen Moore, BA

CONTACT

317-274-0930 [email protected]

Trial snapshot

StatusNOT_YET_RECRUITING

PhaseNA

Enrollment130

Start dateMar 2026

Last updatedMar 20, 2026

Condition

Germ Cell Cancer Metastatic

Locations shown

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions